Asia
Companies from across the globe provide updates to their business and pipeline.
Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.
Helen Tayton-Martin, Adaptimmune’s chief business officer and co-founder, said the partnership with Astellas builds upon and extends an existing collaboration focused on gene editing of iPSC cells.
Clinicians and scientists from National Heart Centre Singapore, Duke-NUS Medical School’s Cardiovascular & Metabolic Disorders Programme (CVMD) and SingHealth Duke-NUS Academic Medical Centre (AMC)s’ discovery of a key driver of fibrosis and inflammation in human diseases is now moving rapidly toward the clinic.
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week’s appointments.
In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.
Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP-201 compared with data from studies of current standard of care therapy for AD
Pharma and biotech companies from across the globe provide business and pipeline updates.
The funds will be used to support the development of its lead clinical assets under development as cancer treatments.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what the coming year is likely to hold for their particular sphere.
PRESS RELEASES